DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination

Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Therapeutic Equivalence

Intervention: BAY98-7111 (Drug); Naproxen Sodium (Aleve, BAYH6689) (Drug); Diphenhydramine HCl (Drug); BAY98-7111 (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer


The purpose of the current trial is to evaluate the bioavailability of a single oral dose of naproxen sodium 440 mg and DPH HCL 50 mg under fasting and fed conditions and currently marketed single ingredient products containing naproxen sodium (2 x AleveŽ 220 mg tablets) or DPH HCL (2 Allergy Relief x 25 mg tablets) under fasting conditions.

Clinical Details

Official title: A Bioavailability Study of Naproxen Sodium and Diphenhydramine Hydrochloride Under Fasting Conditions and Naproxen Sodium and Diphenhydramine Hydrochloride Combination Under Fasting and Fed Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome:

AUC(0-tn) (area under the measurement versus time curve from time 0 to the last data point) of naproxen sodium

AUC(0-tn) (area under the measurement versus time curve from time 0 to the last data point) of DPH HCL(Diphenhydramine Hydrochloride)

Cmax(Maximum drug concentration) in plasma of naproxen sodium

Cmax(Maximum drug concentration) in plasma of DPH HCL(Diphenhydramine Hydrochloride)

Secondary outcome: Number of participants with adverse events as a measure of safety and tolerability


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.


Inclusion Criteria:

- Health, ambulatory male and female subjects between 18 to 55 years of age inclusive

- Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg

(110 lbs)

- Results of screening and clinical laboratory tests are within normal range or

considered not clinically significant by the Principal Investigator or Sponsor

- Female subjects of childbearing potential must be using a medically acceptable form

of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e. g., oral or patch contraceptives, intrauterine device, Depo-Provera, or a double barrier and have a negative pregnancy test at Screening and Day 0 for each Dosing Period. Female subjects of non childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy Exclusion Criteria:

- History of hypersensitivity to aspirin (ASA), naproxen sodium, NSAIDs, acetaminophen,

DPH HCL, and similar pharmacological agents or components of the products

- History of hypersensitivity to any of the food products in the standardized breakfast

or cannot consume all food/beverage items contained in the standardized breakfast

- Have taken ASA, ASA-containing products, acetaminophen or any other NSAID (OTC or

prescription) 7 days prior to dosing or during the Dosing Periods, other than trial treatment

- Use of any over-the-counter or prescription medications (except acceptable forms of

birth control) within 10 days prior to dosing or throughout the trial, unless in the opinion of the Investigator, the medication will not interfere with the trial procedures, data integrity, or compromise the safety of the subject

- Recently had (past 30 days) or plan to have surgery, an invasive procedure, tattoos

or piercings during the trial or 1-2 weeks after treatment

- Loss of blood in excess of 500 ml within 56 days of the first dose of trial treatment

(e. g., donation, plasmapheresis or injury)

- History of gastrointestinal bleeding or perforation, related to previous NSAID

therapy or active or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding)

- Evidence or history of clinically significant hematological, renal, endocrine,

pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases or malignancies

- Smokers or currently consuming any type of tobacco product(s) including any smoking

cessation nicotine-containing product (e. g., nicotine patch, nicotine gum)

- Have taken any vitamin or herbal supplement within 7 days prior to dosing or refuse

to refrain from use during the trial

Locations and Contacts

Hackensack, New Jersey 07601, United States
Additional Information

Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Click here to find results for studies related to Bayer Healthcare products.

Starting date: January 2012
Last updated: August 20, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017